PTIX (Protagenic) שינוי ברווח נקי למניה בשנה הנוכחית

Protagenic Therapeutics (PTIX) demonstrates stability in its relative annual growth of net income per share, driven by streamlined air delivery of research components. Business revenues rely on the future release of treatments for anxiety disorders, although dependence on investments and the risk of test failure pose threats. Meanwhile, the level of 0.00 represents the current value of this indicator, capturing the adaptability of the PTIX model to market changes.

Protagenic Therapeutics (PTIX) maintains a costly cold chain for the transportation of biologics, which directly impacts operating expenses. The earnings per share (EPS) trend measures the percentage deviation of current financial results from the previous year's figures, reflecting the efficiency of cost management. Analyzing the annual EPS change allows investors to assess the business's resilience to logistics costs and the real rate of capital growth.